Darolutamide (Nubeqa, BAY1841788) + Placebo
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Prostate Cancer Non-Metastatic
Conditions
Prostate Cancer Non-Metastatic, Castration-Resistant
Trial Timeline
Sep 12, 2014 → Jun 14, 2021
NCT ID
NCT02200614About Darolutamide (Nubeqa, BAY1841788) + Placebo
Darolutamide (Nubeqa, BAY1841788) + Placebo is a phase 3 stage product being developed by Bayer for Prostate Cancer Non-Metastatic. The current trial status is completed. This product is registered under clinical trial identifier NCT02200614. Target conditions include Prostate Cancer Non-Metastatic, Castration-Resistant.
What happened to similar drugs?
20 of 20 similar drugs in Prostate Cancer Non-Metastatic were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04736199 | Phase 3 | Completed |
| NCT02200614 | Phase 3 | Completed |
Competing Products
20 competing products in Prostate Cancer Non-Metastatic